Tilray Medical has made history as the first company to receive formal authorization from the Italian Ministry of Health to import and distribute its branded medical marijuana flower products across Italy.
Beginning this month, Tilray-branded flower is available for distribution to pharmacies nationwide through its subsidiary, FL Group. Three products have been approved for therapeutic use: Tilray THC 25%, Tilray THC 18%, and Tilray THC 9% / CBD 9%.
“This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being,” said Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International. She credited the Italian government for establishing a regulatory framework that ensures patient access to safe and consistent cannabinoid-based therapies.
The products are produced in EU-GMP certified facilities and are part of Tilray’s broader European expansion. The company now has medical cannabis operations in Germany, Italy, Portugal, Poland, and the United Kingdom, offering a wide array of products for patients with qualifying conditions.
Tilray Medical, a division of Tilray Brands, was among the first licensed producers in Canada and has since built certified production hubs in Portugal and Germany. The company distributes several well-known brands, including Broken Coast, Redecan, and Good Supply.
This development further cements Tilray’s position as a leader in the European medical marijuana market and marks a major step forward for patients in Italy who rely on therapeutic cannabis.
